Healthcare Jun 23, 2021 09:24 AM (GMT+8) · EqualOcean
Zhao Haichun, an analyst at Guojin securities, commented on the approval of China's first cart, saying that yijilisai injection is a cell therapy drug that is used to edit and transform patients' autologous T cells by means of genetic engineering and then transfused back to patients. The indication is for adult patients with relapsed or refractory large B-cell lymphoma after second-line or above systemic treatment. It is the first cell therapy product with epoch-making significance in China. Its approval marks that China's pharmaceutical industry has entered a new historical stage of fully possessing innovative treatment methods such as chemical small molecules, biological macromolecules and cell gene therapy.